Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

Supplements and Featured Publications, Navigating New Data in the Breast Cancer Treatment Paradigm, Volume 1, Issue 1

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School, discusses findings from the phase 3 DESTINY-Breast12 trial (NCT04739761) investigating fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with HER2-positive advanced or metastatic breast cancer with or without brain metastases.

Disclosures: Dr Lin reports consultant/advisory/steering committee participation with Artera, AstraZeneca, Bluepoint Medicines, Daiichi Sankyo, Eisai, Janssen, Olema Pharmaceuticals, Seagen, and Stemline Therapeutics; travel support from Olema Pharmaceuticals; institutional research support from AstraZeneca, Genentech, Olema Pharmaceuticals, Pfizer, Seagen, and Zion Pharmaceuticals; and royalties from book chapters from UpToDate.